T2 Biosystems Announces Presentations at ASM Microbe 2017 Conference
COMPANY INDUSTRY & SCIENCE SHOWCASE: “Application of Rapid, Blood Culture-Free Diagnostics in the
Presenters: Dr.
Overview: This symposium offers expert guidance on the application of T2MR technology in the
Time: June 2, 1:30-
Location: Theater B
COMPANY INDUSTRY & SCIENCE SHOWCASE: “Managing Sepsis in the Golden Hour: Controlling Costs and Improving Patient Care through Diagnostic Testing”
Presenters: Dr.
Overview: This symposium will provide a forum for peer-to-peer learning on the proven impact of T2MR technology. This session will review the positive patient care impact and economic benefits realized by using the only
Time: June 4, 12:30 -
Location: Theater B
SESSION: “Debates in Medical Mycology”
Debate 2: “Management of Invasive Candidiasis - T2 is the New Standard in Managing IC”
Session Number: #116
Presenter:
Time:
LATE BREAKER POSTER SESSION: “Assessing High Sensitivity Direct from Blood Pathogen Detection”
Poster Number: #056a
Presented by:
Presenting Authors:
Time:
Location: Exhibit Hall D, Exhibit and Poster Hall
POSTER PRESENTATION: “Clinical Urine Specimens as a Sample Matrix for T2 Magnetic Resonance Technology”
Poster Number: #454
Presented by: Indiana University School of Medicine
Presenting Author: T. Kieffer,
Time:
Location: Exhibit Hall D, Exhibit and Poster Hall
POSTER PRESENTATION: “T2 Magnetic Resonance Technology for the Diagnosis of Candidemia in Low Volume Whole Blood Specimens”
Poster Number: #464
Presented by: Indiana University School of Medicine
Presenting Author: T. Kieffer,
Time:
Location: Exhibit Hall D, Exhibit and Poster Hall
POSTER PRESENTATION: “Diagnosis of Fungal Peritonitis Caused by Candida spp. Using T2 Magnetic Resonance Technology on Dialysate Matrix”
Poster Number: #473
Presented by: Indiana University School of Medicine
Presenting Author: T. Kieffer,
Time:
Location: Exhibit Hall D, Exhibit and Poster Hall
About T2 Biosystems
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2017, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Company Contact:Darlene Deptula-Hicks ,T2 Biosystems SVP & Chief Financial Officer ddeptula@t2biosystems.com 603-553-5803 Media Contact:Matthew McKillip ,T2 Biosystems mmckillip@t2biosystems.com 518-577-3466 Investor Contact:Tucker Elcock , Teneo Strategy Tucker.Elcock@teneostrategy.com 212-886-9319